ADMA Biologics has delivered a very large 5 year share price gain, yet the stock is down sharply over the past year, which naturally raises the question of whether today's valuation is still supported by its earnings power. For anyone tracking the biotech space, the issue now is whether the current US$9.52 price fairly reflects what the business is actually earning.
- Over the past 5 years the share price has risen by roughly 7x, which puts a lot of weight on the idea that ADMA Biologics can continue to translate its plasma products into growing earnings.
- The business model depends heavily on expanding plasma collection and processing efficiency, which can influence both profit margins and how quickly earnings may convert into steady cash flow.
- There is a second opinion on ADMA Biologics worth weighing. See what analysts think ADMA Biologics's shares could be worth.
The issue now is whether the earnings that underpin ADMA Biologics are strong and resilient enough to justify where the stock trades today.
If you are weighing whether ADMA Biologics' earnings justify its current valuation, it can help to compare that question across 30 high quality undervalued stocks.
Is ADMA Biologics Still Cheap on Earnings?
The P/E ratio is a useful lens for ADMA Biologics because investors are focused on how much they are paying for each dollar of current earnings. At roughly 12.6x earnings, the stock trades below the broader biotech industry average of about 17.3x and also below peers near 38.2x, so the market is assigning a lower earnings multiple than many comparable biotechs.
The Fair Ratio suggests a P/E level that would better reflect ADMA Biologics' specific growth profile, profitability and risk. Since the current 12.6x sits below that tailored benchmark, the shares screen as undervalued on this earnings lens, although the gap always needs to be weighed against the quality and durability of those reported profits. Explore the numbers behind ADMA Biologics's P/E valuation.
The ADMA Biologics Narrative: What Would Justify Today's Price?
Narratives for ADMA Biologics pick up where this valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to play out for the stock to be worth materially more or less than it is today. Each scenario lays out the assumptions behind its view of fair value in plain terms, so you can later compare those expectations with the actual results reported on Simply Wall St's Community page.
One of the top community narratives on ADMA Biologics: 46% undervalued
"Commercial-scale implementation of the FDA-approved yield enhancement process is producing a 20%+ increase in bulk immunoglobulin output, expected to drive sustained gross margin expansion…"
Discover why this Narrative puts ADMA Biologics at 46% undervalued.
One more angle on ADMA Biologics that could change the story
Share price history and current earnings multiples only tell part of the story. Professional estimates for where this business might be a few years from now give you a different lens on what today’s price really implies. Explore where analysts expect ADMA Biologics to be in a few years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com